Frovatriptan
From Wikipedia, the free encyclopedia
Frovatriptan Frova
 |
|
|
Frovatriptan
|
|
| Systematic (IUPAC) name | |
| 6-methylamino-6,7,8,9-tetrahydro -5H-carbazole-3-carboxamide |
|
| Identifiers | |
| CAS number | 158930-17-7 |
| ATC code | N02CC07 |
| PubChem | 5284561 |
| DrugBank | APRD00270 |
| Chemical data | |
| Formula | C14H17N3O |
| Mol. weight | 243.304 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 20-30% |
| Metabolism | Hepatic |
| Half life | 26 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Frovatriptan (Frova®) is a triptan drug developed by Endo Pharmaceuticals for the treatment of migraine headaches. Frovatriptan causes vasoconstriction of arteries and veins that supply blood to the head. It is available as 2.5 mg tablets.
Frovatriptan has mean terminal elimination half-life of approximately 26 hours, which is substantially longer than for other triptans.
Frovatriptan is available only by prescription in the United States.
[edit] External links
- Frova (manufacturer's website)
- Frovatriptan (patient information)
| Triptans (N02CC) edit | ||
|---|---|---|
|
Almotriptan, Eletriptan, Frovatriptan, Naratriptan, Rizatriptan, Sumatriptan, Zolmitriptan |
||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
